Abrogation of CC Chemokine Receptor 9 Ameliorates Ventricular Electrical Remodeling in Mice After Myocardial

Yan Huang1,2,3, Hua-Sheng Ding1,2,3, Tao Song1,2,3

  • 1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.

Insights

CC chemokine receptor 9 (CCR9) knockout prevents electrical remodeling after myocardial infarction (MI) by normalizing ion currents and calcium homeostasis. This suggests CCR9 is a potential therapeutic target for treating MI-induced arrhythmias.

Area of Science:

  • Cardiology
  • Immunology
  • Molecular Biology

Background:

  • Myocardial infarction (MI) causes significant structural and electrical remodeling in the heart.
  • CC chemokine receptor 9 (CCR9) plays a role in inflammatory cell recruitment post-MI.
  • Previous research indicated CCR9 knockout improves structural remodeling after MI.

Purpose of the Study:

  • To investigate the influence of CCR9 on electrical remodeling following MI.
  • To explore CCR9 as a potential therapeutic target for improving MI prognosis.

Main Methods:

  • Mice models with and without CCR9 knockout were subjected to MI or sham procedures.
  • Whole-cell patch clamp electrophysiology recorded action potential duration (APD) and ion currents (ICaL, Ito).
  • Confocal microscopy assessed calcium transients and sarcoplasmic reticulum (SR) calcium content.
  • Multielectrode array (MEA) measured ventricular conduction velocity.
  • Western blot analyzed connexin 43 expression.

Main Results:

  • MI induced prolonged APD90, increased ICaL, and decreased Ito, which were attenuated by CCR9 knockout.
  • CCR9 knockout reversed MI-induced reductions in calcium transient and SR calcium content.
  • Conduction velocity was significantly improved in CCR9 knockout mice post-MI.
  • Connexin 43 expression, reduced by MI, was improved with CCR9 knockout.

Conclusions:

  • CCR9 knockout prevents MI-induced electrical remodeling by normalizing ion currents, calcium handling, and gap junction expression.
  • These effects help maintain normal APD and cardiac conduction.
  • CCR9 emerges as a promising therapeutic target for managing MI-related arrhythmias.

Related Concept Videos